Revolutionary new cancer treatment tested at Sheba Medical Center

New cancer treatment undergoing clinical tests at Sheba hospital in central Israel represents a 'sea change' called a 'breakthrough' by FDA

Arutz Sheva Staff ,

Professor Gal Markel
Professor Gal Markel

An innovative, non-pharmaceutical treatment that filters the blood of cancer patients, similar to dialysis, is currently undergoing clinical trials at the Sheba Medical Center in Israel. Called immunopheresis, this revolutionary technology removes proteins produced by malignant cells that block the body's natural immune system, enabling the body to better attack and destroy cancerous tumor cells.

The 40-patient clinical study was conceived and led by Professor Gal Markel, director of the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. It will treat patients with various types of cancer, including breast cancer, resistant metastatic melanoma, renal cell carcinoma and lung cancer.

Professor Markel explained that certain cancer cells can protect themselves from the body's immune system by producing proteins that circulate in the patient's bloodstream and sabotage the ability of the immune cells to battle disease. He said that the existence of these proteins has been known since the 1990s, but until now, no one knew how to destroy them. Prof. Markel added that the technology, manufactured by Immunicom of San Diego and designated by the FDA as a "breakthrough," has the ability to "neutralize the cancer by filtering those proteins out of the bloodstream so that the patient's own immune system can fight effectively, either alone or in tandem with existing immunotherapy drugs."

Calling it a "sea change" from traditional standards of care, Prof. Markel noted that this innovation offers the potential to effectively treat a wide variety of cancer types, including those that have not previously responded to other treatment strategies, resulting in much better clinical outcomes with fewer side effects.

“The most important thing for me is to improve cancer patients’ survival and quality of life,” Markel said. "With this trial, there is real hope that we can really make that happen.”